IFNA2 and melanoma: The results of this groundbreaking trial led the United States Food and Drug Administration (FDA) to approve IFN-α2b for commercial use, and IFN-α2b under the ECOG 1684 protocol became the standard of care for high-risk operable melanoma patients.